|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pepe MS, Etzioni R, Feng Z, Potter JD,
Thompson ML, Thornquist M, Winget M and Yasui Y: Phases of
biomarker development for early detection of cancer. J Natl Cancer
Inst. 93:1054–1061. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walczak H and Krammer PH: The CD95
(APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res.
256:58–66. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomadaki H and Scorilas A: BCL2 family of
apoptosis-related genes: Functions and clinical implications in
cancer. Crit Rev Clin Lab Sci. 43:1–67. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sträter J, Hinz U, Hasel C, Bhanot U,
Mechtersheimer G, Lehnert T and Möller P: Impaired CD95 expression
predisposes for recurrence in curatively resected colon carcinoma:
Clinical evidence for immunoselection and CD95L mediated control of
minimal residual disease. Gut. 54:661–665. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Korkolopoulou P, Saetta AA, Levidou G,
Gigelou F, Lazaris A, Thymara I, Scliri M, Bousboukea K,
Michalopoulos NV, Apostolikas N, et al: c-FLIP expression in
colorectal carcinomas: Association with Fas/FasL expression and
prognostic implications. Histopathology. 51:150–156. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strand S, Hofmann WJ, Hug H, Müller M,
Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR:
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing
tumor cells-a mechanism of immune evasion? Nat Med. 2:1361–1366.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deveraux QL, Stennicke HR, Salvesen GS and
Reed JC: Endogenous inhibitors of caspases. J Clin Immunol.
19:388–398. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chantalat L, Skoufias DA, Kleman JP, Jung
B, Dideberg O and Margolis RL: Crystal structure of human survivin
reveals a bow tie-shaped dimer with two unusual alpha-helical
extensions. Mol Cell. 6:183–189. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dohi T, Okada K, Xia F, Wilford CE, Samuel
T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An
IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mahotka C, Wenzel M, Springer E, Gabbert
HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: Two novel
splice variants of the apoptosis inhibitor survivin with different
antiapoptotic properties. Cancer Res. 59:6097–6102. 1999.PubMed/NCBI
|
|
14
|
Hamilton SR and Aaltonen LA: World Health
Organization Classification of TumoursPathology and Genetics of
Tumours of the Digestive System. IARC Press; Lyon: pp. 1042000
|
|
15
|
Kalliakmanis JG, Kouvidou Ch, Latoufis C,
Kouvatseas G, Anagnostakis D, Papatheodoridis G, Koskinas J and
Archimandritis A: Survivin expression in colorectal carcinomas:
Correlations with clinicopathological parameters and survival. Dig
Dis Sci. 55:2958–2964. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi J and Chang H: The expression of MAGE
and SSX, and correlation of COX2, VEGF, and survivin in colorectal
cancer. Anticancer Res. 32:559–564. 2012.PubMed/NCBI
|
|
17
|
Hernandez JM, Farma JM, Coppola D, Hakam
A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D:
Expression of the antiapoptotic protein survivin in colon cancer.
Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xi RC, Biao WS and Gang ZZ: Significant
elevation of survivin and livin expression in human colorectal
cancer: Inverse correlation between expression and overall
survival. Onkologie. 34:428–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ponnelle T, Chapusot C, Martin L, Bouvier
AM, Plenchette S, Faivre J, Solary E and Piard F: Cellular
localisation of survivin: Impact on the prognosis in colorectal
cancer. J Cancer Res Clin Oncol. 131:504–510. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shintani M, Sangawa A, Yamao N and
Kamoshida S: Immunohistochemical expression of nuclear and
cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp
Pathol. 6:2919–2927. 2013.PubMed/NCBI
|
|
21
|
Qi G, Tuncel H, Aoki E, Tanaka S, Oka S,
Kaneko I, Okamoto M, Tatsuka M, Nakai S and Shimamoto F:
Intracellular localization of survivin determines biological
behavior in colorectal cancer. Oncol Rep. 22:557–562.
2009.PubMed/NCBI
|
|
22
|
McKenzie JA, Liu T, Goodson AG and
Grossman D: Survivin enhances motility of melanoma cells by
supporting Akt activation and {alpha}5 integrin upregulation.
Cancer Res. 70:7927–7937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang M, Coen JJ, Suzuki Y, Siedow MR,
Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU
and Chakravarti A: Survivin is a potential mediator of prostate
cancer metastasis. Int J Radiat Oncol Biol Phys. 78:1095–1103.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chu XY, Chen LB, Wang JH, Su QS, Yang JR,
Lin Y, Xue LJ, Liu XB and Mo XB: Overexpression of survivin is
correlated with increased invasion and metastasis of colorectal
cancer. J Surg Oncol. 105:520–528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiaoyuan C, Longbang C, Jinghua W,
Xiaoxiang G, Huaicheng G, Qun Z and Haizhu S: Survivin: A potential
prognostic marker and chemoradiotherapeutic target for colorectal
cancer. Ir J Med Sci. 179:327–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen W, Tu JK, Wang XH and Fu ZX:
Oncolytic adenovirus mediated Survivin RNA interference and
5-fluorouracil synergistically suppress the lymphatic metastasis of
colorectal cancer. Oncol Rep. 24:1285–1290. 2010.PubMed/NCBI
|
|
27
|
Li JH, He WJ and He YJ: Expression and
clinical significance of Survivin and Livin in DukesoB colorectal
cancer. Ai Zheng. 26:547–551. 2007.(In Chinese). PubMed/NCBI
|
|
28
|
Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF,
Chiang H and Jin JS: Expression of survivin and cortactin in
colorectal adenocarcinoma: Association with clinicopathological
parameters. Dis Markers. 26:9–18. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suzuki A, Hayashida M, Ito T, Kawano H,
Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell
cycle entry by the competitive interaction with Cdk4/p16(INK4a) and
Cdk2/cyclin E complex activation. Oncogene. 19:3225–3234. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yagihashi A, Asanuma K, Nakamura M, Araya
J, Mano Y, Torigoe T, Kobayashi D and Watanabe N: Detection of
anti-survivin antibody in gastrointestinal cancer patients. Clin
Chem. 47:1729–1731. 2001.PubMed/NCBI
|
|
31
|
Wang YQ, Zhang HH, Liu CL, Xia Q, Wu H, Yu
XH and Kong W: Correlation between auto-antibodies to survivin and
MUC1 variable number tandem repeats in colorectal cancer. Asian Pac
J Cancer Prev. 13:5557–5562. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rohayem J, Diestelkoetter P, Weigle B,
Oehmichen A, Schmitz M, Mehlhorn J, Conrad K and Rieber EP:
Antibody response to the tumor-associated inhibitor of apoptosis
protein survivin in cancer patients. Cancer Res. 60:1815–1817.
2000.PubMed/NCBI
|
